FOLFOX alone or combined to rilotumumab or panitumumab as first-line treatment in patients (pts) with advanced gastroesophageal adenocarcinoma (AGEA): An open-label, randomized phase II trial (PRODIGE 17 ACCORD 20 MEGA).

David Malka,Florence Castan,Éric François,Olivier Bouche,Jaafar Bennouna,François Ghiringhelli,Christelle de la Fouchardiere,Christophe Borg,Emmanuelle Samalin,Jean-Baptiste Bachet,Jean-Luc Raoul,Frédérique Cvitkovic,Laurent Miglianico,Leila Bengrine-Lefevre,Laetitia Dahan,Cédric Lecaille,Thomas Aparicio,H Perrier,Sophie Gourgou,Julien Taieb

FOLFOX alone or combined to rilotumumab or panitumumab as first-line treatment in patients (pts) with advanced gastroesophageal adenocarcinoma (AGEA): An open-label, randomized phase II trial (PRODIGE 17 ACCORD 20 MEGA).

2015

4013 Background: EGFR and HGF/c-Met pathways are often deregulated in AGEA. We assessed whether EGFR or HGF inhibition with panitumumab or rilotumumab is beneficial in the first-line treatment of p...

Keywords:

Oncology
Pathology
FOLFOX
Rilotumumab
Adenocarcinoma
Medicine
Internal medicine
Panitumumab
first line treatment
open label
in patient
gastroesophageal adenocarcinoma

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations